Combined oral estro-progestative contraceptives is associated with venous thromboembolism in women of reproductive age. Care providers typically rely on women's characteristics, medical history and on family history to select most appropriate contraceptives, in an effort to reduce risks of venous thromboembolism. This position paper discusses the use of a new prediction tool (Pill Protect®), available in Switzerland, which adds genetic profiling to clinical characteristics with the aim of predicting individual contraceptive-related thrombotic risks and individualize contraceptive prescription. After reviewing the available data regarding this tool, we believe that its development and validation process may be incomplete and that there is uncertainty whether the use of Pill Protect® would lead to better health outcomes. Until we understand the necessarily rigorous scientific validation of this tool, we urge caution to physicians and women who may want to use it.